Abstract |
High gastrin releasing peptide receptor (GRPR) expression is associated with numerous cancers including prostate and breast cancer. The aim of the current study was to develop a 55Co-labeled PET agent based on GRPR antagonist RM26 for visualization of GRPR-expressing tumors. Labeling with 57Co and 55Co, stability, binding specificity, and in vitro and in vivo characteristics of 57Co-NOTA-PEG2-RM26 were studied. NOTA-PEG2-RM26 was successfully radiolabeled with 57Co and 55Co with high yields and demonstrated high stability. The radiopeptide showed retained binding specificity to GRPR in vitro and in vivo. 57Co-NOTA-PEG2-RM26 biodistribution in mice was characterized by rapid clearance of radioactivity from blood and normal non-GRPR-expressing organs and low hepatic uptake. The clearance was predominantly renal with a low degree of radioactivity reabsorption. Tumor-to-blood ratios were approximately 200 (3 h pi) and 1000 (24 h pi). The favorable biodistribution of cobalt-labeled NOTA-PEG2-RM26 translated into high contrast preclinical PET/CT (using 55Co) and SPECT/CT (using 57Co) images of PC-3 xenografts. The initial biological results suggest that 55Co-NOTA-PEG2-RM26 is a promising tracer for PET visualization of GRPR-expressing tumors.
|
Authors | Bogdan Mitran, Helge Thisgaard, Ulrika Rosenström, Johan Hygum Dam, Mats Larhed, Vladimir Tolmachev, Anna Orlova |
Journal | Contrast media & molecular imaging
(Contrast Media Mol Imaging)
Vol. 2017
Pg. 6873684
( 2017)
ISSN: 1555-4317 [Electronic] England |
PMID | 29097932
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Cobalt Radioisotopes
- Receptors, Bombesin
- Bombesin
|
Topics |
- Animals
- Bombesin
(antagonists & inhibitors)
- Cobalt Radioisotopes
(pharmacokinetics)
- Heterografts
- Humans
- Male
- Mice
- Positron-Emission Tomography
(methods)
- Prostatic Neoplasms
(diagnostic imaging)
- Receptors, Bombesin
(analysis, antagonists & inhibitors, metabolism)
- Tissue Distribution
|